

## Financial Tear Sheet

### Corporate Profile

Bioverativ is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company's mission is to create progress for patients where they need it most, and its hemophilia therapies, when launched, represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit [www.bioverativ.com](http://www.bioverativ.com) or follow @Bioverativ on Twitter.


### Primary IR Contact

Investor Relations  
**Phone:** 781-663-4360  
**E-mail:** [IR@bioverativ.com](mailto:IR@bioverativ.com)

### Stock Information

BIVV (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Price	<b>\$104.98</b>
Change (%)	▲ 0.33 (0.32%)
Volume	792,967
52 Week Low	\$48.14
Market Cap	\$11,361,318,147
Rolling EPS	2.74
PE Ratio	38.26
Shares Outstanding	108,223,644
Data as of	03/08/18 10:41 a.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.



### Recent News & Upcoming Events

03/06/18  
Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease

02/14/18  
Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A

02/13/18  
Bioverativ Reports Fourth Quarter and Full Year 2017 Performance

There are currently no events scheduled.

# SEC Filings

Filing Date	Form
04/10/18	SC 13G/A
03/19/18	15-12B
03/08/18	4
03/08/18	4